{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:45:44Z","timestamp":1791013544144,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.ctrv.2005.10.001","type":"journal-article","created":{"date-parts":[[2005,11,18]],"date-time":"2005-11-18T12:15:12Z","timestamp":1132316112000},"page":"591-602","source":"Crossref","is-referenced-by-count":66,"title":["Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies"],"prefix":"10.1016","volume":"31","author":[{"given":"Graham","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5555","key":"10.1016\/j.ctrv.2005.10.001_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.295.5555.612","article-title":"Cancer research. Taking garbage in, tossing cancer out","volume":"295","author":"Garber","year":"2002","journal-title":"Science"},{"issue":"4 Suppl","key":"10.1016\/j.ctrv.2005.10.001_bib2","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1471-4914(02)02315-8","article-title":"Proteasome inhibition: a novel approach to cancer therapy","volume":"8","author":"Adams","year":"2002","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.ctrv.2005.10.001_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.ctrv.2005.10.001_bib4","first-page":"835","article-title":"Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumour xenografts","volume":"2","author":"Williams","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"5293","key":"10.1016\/j.ctrv.2005.10.001_bib5","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.ctrv.2005.10.001_bib6","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","article-title":"Proteasome inhibition in cancer: development of PS-341","volume":"28","author":"Adams","year":"2001","journal-title":"Semin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib8","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumour agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2005.10.001_bib9","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2003.06.001","article-title":"Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2005.10.001_bib10","first-page":"3719","article-title":"Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341","volume":"6","author":"Frankel","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2005.10.001_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1535-7163.279.3.3","article-title":"The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumours in vivo","volume":"3","author":"Kamat","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2005.10.001_bib13","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib14","first-page":"64a","article-title":"A phase I\/II trial of VELCADE and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM)","volume":"104","author":"Berenson","year":"2004","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ctrv.2005.10.001_bib15","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2005.10.001_bib16","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2005.10.001_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/0929867033368231","article-title":"Proteasome inhibitors as therapeutic agents: current and future strategies","volume":"10","author":"Delcros","year":"2003","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.ctrv.2005.10.001_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"5288","key":"10.1016\/j.ctrv.2005.10.001_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1126\/science.274.5288.784","article-title":"TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB","volume":"274","author":"Wang","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: enhanced anti-tumour therapy through increased apoptosis by inhibition of NF-kappaB","volume":"5","author":"Wang","year":"1999","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ctrv.2005.10.001_bib24","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition","volume":"61","author":"Cusack","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2005.10.001_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0360-3016(01)01446-8","article-title":"Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB","volume":"50","author":"Russo","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ctrv.2005.10.001_bib26","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2005.10.001_bib28","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumour cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2005.10.001_bib29","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2005.10.001_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.ctrv.2005.10.001_bib31","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.ctrv.2005.10.001_bib32","first-page":"4342","article-title":"Tumour growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2005.10.001_bib33","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2005.10.001_bib34","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2005.10.001_bib35","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumours with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2005.10.001_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2005.10.001_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2005.10.001_bib38","first-page":"S103","article-title":"Survival, duration of response, and time to progression with bortezmib in patients with relapsed and refractory multiple myeloma: an update with additional follow-up","volume":"5","author":"Richardson","year":"2004","journal-title":"Hematol J"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2005.10.001_bib39","first-page":"S129","article-title":"The safety of prolonged therapy with the proteasome inhibitor bortezomib (VELCADE) in relapsed and\/or refractory multiple myeloma (MM)","volume":"5","author":"Berenson","year":"2004","journal-title":"Hematol J"},{"issue":"2","key":"10.1016\/j.ctrv.2005.10.001_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.ctrv.2005.10.001_bib41","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2005.10.001_bib42","first-page":"s1","article-title":"Bortezomib at first relapse is superior to high-dose dexamethasone and mnore effective than when given later in relapsed multiple myeloma","volume":"90","author":"Sonneveld","year":"2005","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2005.10.001_bib43","first-page":"S130","article-title":"Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma","volume":"5","author":"Jagannath","year":"2004","journal-title":"Hematol J"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib44","doi-asserted-by":"crossref","first-page":"659a","DOI":"10.1182\/blood.V104.11.2399.2399","article-title":"Bortezomib Velcade\u2122)+Adriamycin\u2122+thalidomide+dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM)","volume":"104","author":"Hollmig","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib45","doi-asserted-by":"crossref","first-page":"665a","DOI":"10.1182\/blood.V104.11.2421.2421","article-title":"A phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstrom\u2019s macroglobulinemia (WM): encouraging preliminary results","volume":"104","author":"Chanan-Khan","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib46","doi-asserted-by":"crossref","first-page":"413a","DOI":"10.1182\/blood.V104.11.1480.1480","article-title":"Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM)","volume":"104","author":"Zangari","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"issue":"16S","key":"10.1016\/j.ctrv.2005.10.001_bib49","first-page":"598s","article-title":"Bortezomib (VELCADE) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study","volume":"23","author":"Harousseau","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib50","first-page":"64a","article-title":"VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma","volume":"104","author":"Alexanian","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2005.10.001_bib51","first-page":"149","article-title":"A phase I\/II national, multi-center, open-label study of Velcade plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients","volume":"90","author":"Mateos","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ctrv.2005.10.001_bib52","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2005.10.001_bib53","unstructured":"VELCADE (bortezomib) for injection. Full prescribing information available at: http:\/\/www.millenniumcom\/products\/velcade\/indexasp; 2004. Accessed February 24, 2005."},{"issue":"2","key":"10.1016\/j.ctrv.2005.10.001_bib54","first-page":"S129","article-title":"Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE): the SUMMIT and CREST study group","volume":"5","author":"Richardson","year":"2004","journal-title":"Hematol J"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib57","doi-asserted-by":"crossref","first-page":"175a","DOI":"10.1182\/blood.V104.11.608.608","article-title":"Phase II trial of bortezomib in mantle cell lymphoma","volume":"104","author":"Belch","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib58","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1386.1386","article-title":"Phase II clinical study of bortezomib (VELCADE\u00ae) in patients (pts) with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL) and Hodgkin\u2019s disease (HD)","volume":"104","author":"Strauss","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib59","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1385.1385","article-title":"Phase I\/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-Cell lymphoma","volume":"104","author":"Dunleavy","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib60","doi-asserted-by":"crossref","first-page":"722a","DOI":"10.1182\/blood.V104.11.2638.2638","article-title":"Safety and efficacy of bortezomib (VELCADE\u00ae) for the treatment of relapsed classical Hodgkin\u2019s disease","volume":"104","author":"Younes","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2005.10.001_bib61","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib62","doi-asserted-by":"crossref","first-page":"498a","DOI":"10.1182\/blood.V104.11.1799.1799","article-title":"Phase I dose-escalating trial of bortezomib (VELCADE\u00ae) in combination with idarubicin and cytosine arabinoside in patients with acute myeloid leukemia","volume":"104","author":"Attar","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2005.10.001_bib63","first-page":"52","article-title":"Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma","volume":"17","author":"Mehta","year":"2004","journal-title":"Manag Care Interface"},{"issue":"11","key":"10.1016\/j.ctrv.2005.10.001_bib64","doi-asserted-by":"crossref","first-page":"80a","DOI":"10.1182\/blood.V104.11.268.268","article-title":"Economic evaluation of bortezomib (Velcade) for relapsed and refractory multiple myeloma","volume":"104","author":"Bagust","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib65","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"10.1016\/j.ctrv.2005.10.001_bib66","first-page":"1302","article-title":"Efficacy, safety, and cost of new anticancer drugs","volume":"325","author":"Messori","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ctrv.2005.10.001_bib67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2005.10.001_bib68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2005.10.001_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1702445","article-title":"Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma","volume":"26","author":"Gertz","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2005.10.001_bib70","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737205001994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737205001994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T13:52:46Z","timestamp":1683294766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737205001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0305737205001994"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2005.10.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}